Bedaquiline + Pretomanid + Moxifloxacin + Pyrazinamide


“BPaMZ” is an all-oral TB treatment regimen consisting of bedaquiline (B), pretomanid (Pa), moxifloxacin (M) and pyrazinamide (Z). BPaMZ is currently being tested in those with drug-sensitive (DS-) as well as those with drug-resistant (MDR-) pulmonary tuberculosis (specifically multidrug-resistant TB and mono-resistance to isoniazid and rifampicin) in the pivotal SimpliciTB trial.

Regimen Trials